{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-011888","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.717648+00:00","generated_at":"2026-06-16T05:04:35.368020+00:00","sec_items":["1.01","1.02","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pulse Biosciences cancels $65M+ debt via stock issuance to executive chairman at $6.51/share","bullets":["Issues 10,022,937 shares to Robert W. Duggan at $6.51 (1%+ premium to $6.44 close) in private placement.","Cancels $65M principal plus ~$0.25M accrued interest; loan agreement terminates without fees.","Duggan's beneficial ownership increases from ~62% to ~69% post-closing; no warrants or placement fees.","Transaction expected to close on or about May 8, 2023, subject to customary conditions.","CEO says debt elimination strengthens balance sheet for developing nsPFA cardiac devices."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-011888","json":"https://secwatch.observer/filing/0001437749-23-011888.json","markdown":"https://secwatch.observer/filing/0001437749-23-011888.md","text":"https://secwatch.observer/filing/0001437749-23-011888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923011888/0001437749-23-011888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923011888/plse20230430_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:04:35.368020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16bae25615c6a16990d49ccf0bfb2cc4c2fa2a47","claim":"PULSE BIOSCIENCES, INC. terminated Loan Agreement with Robert W. Duggan valued at Cancellation of $65 million aggregate principal amount plus accrued interest; Loan Agreement termina (effective 2023-04-30).","evidence_excerpt":"Item 1.02 Termination of a Material Definitive Agreement. The description of the termination of the Loan Agreement set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.02 in its entirety.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923011888/0001437749-23-011888-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Robert W. Duggan"},{"label":"Value","value":"Cancellation of $65 million aggregate principal amount plus accrued interest; Loan Agreement termina"},{"label":"Effective","value":"2023-04-30"}],"fact_type":"material_agreement"},{"claim_id":"928b92c6ed932c48bdc676c5c830361b8168a85f","claim":"PULSE BIOSCIENCES, INC. entered into Securities Purchase Agreement with Robert W. Duggan valued at 10,022,937 shares of common stock at $6.51 per share (effective 2023-04-30).","evidence_excerpt":"On Sunday, April 30, 2023, Pulse Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Robert W. Duggan (“Investor”), the Company’s Executive Chairman of the Board of Directors and majority stockholder of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923011888/0001437749-23-011888-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Robert W. Duggan"},{"label":"Value","value":"10,022,937 shares of common stock at $6.51 per share"},{"label":"Effective","value":"2023-04-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}